ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

WPCT Woodford Patient Capital Trust Plc

33.60
0.00 (0.00%)
19 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Woodford Patient Capital Trust Plc LSE:WPCT London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 33.60 33.55 33.90 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Schroder UK Public Private Tst plc Sanofi completes Kymab acquisition (9548U)

09/04/2021 7:00am

UK Regulatory


Woodford Patient Capital (LSE:WPCT)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Woodford Patient Capital Charts.

TIDMSUPP

RNS Number : 9548U

Schroder UK Public Private Tst plc

09 April 2021

Schroder UK Public Private Trust plc (the "Company")

Sanofi completes Kymab acquisition

The Company (LSE: SUPP) is pleased to announce the completion of the sale of its shares in Kymab Group Ltd. ("Kymab") to Sanofi. The Company will receive initial proceeds of approximately US$82 million. Furthermore, the Company has the potential for additional contingent payments of up to US$33 million subject to a deferred purchase price release and Kymab achieving certain development and regulatory milestones.

For further information on the completed transaction, investors can refer to the announcement made by the Company on 11(th) January 2021.

The Company's holding in Kymab has been revalued to GBP70m reflecting the terms of the agreed sale generating a fair value gain of GBP52m when compared with the holding value of GBP18m as at 30 September 2020. The Company intends to publish a full portfolio analysis at the time of the Company's Annual Report for the year ended 31 December 2020 alongside the audited NAV as at 31 December 2020, which is expected to be announced later this month.

The Company intends to use the proceeds to pay down its loan balance, support some of its portfolio companies with follow-on capital and to make new investments into both public and private companies.

Enquiries:

Schroder Investment Management Limited

 
 Estelle Bibby (Press)               0207 658 3431 
 Gareth Faith (Company Secretary)    0207 658 5264 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQEKLBBFZLXBBB

(END) Dow Jones Newswires

April 09, 2021 02:00 ET (06:00 GMT)

1 Year Woodford Patient Capital Chart

1 Year Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

1 Month Woodford Patient Capital Chart

Your Recent History

Delayed Upgrade Clock